(Date:1/7/2009)...ed at 37 weeks have double the troubles of those b...althDay News) -- Women having an elective repeat C...ks into their pregnancy to have the baby, if there...new study found. , Delivering just two weeks earl...ems, such as trouble breathing, infection and low ...
(Date:1/7/2009)...hows 73 Percent Increase in Patients Unable to Pay... Patients Visiting Hospital ERs , , SACRAMENTO, C...the nation is having a dramatic impact on Californ...eased special report by the California Hospital As...on a survey conducted in November 2008 among hospi...
(Date:1/7/2009)...TER, Ill., Jan. 7 BrainLAB, Inc., a leader in,sof...edical treatments,announces a new, customer-focuse... consideration of continued growth and an expandin...les and support structures, customers will benefit...zation. Streamlined,responsibilities, communicatio...
(Date:1/7/2009)...Ore., Jan. 7 Synthetech, Inc.,(OTC Bulletin Board...rovement,Awards for their outstanding accomplishme...& Security (EHS&S) Planning and Operations...ds are presented by the Synthetic Organic,Chemical...y ChemStewards,SOCMA,s EHS&S improvement initi...
Breaking Medicine News(10 mins):Health News:Early Elective C-Sections Produce Complications 2Health News:Early Elective C-Sections Produce Complications 3Health News:Economic Downturn Takes Toll on California Hospitals 2Health News:BrainLAB, Inc. Announces New, Streamlined Surgery Business Division 2Health News:Synthetech Earns National Recognition for Performance Improvement Program 2Health News:Synthetech Earns National Recognition for Performance Improvement Program 3...17 packets of counterfeit condoms of Durex best-se...n by British authorities.// A Durex spokeswoman s...fety' of the fakes. The number of these fakes that...These counterfeits came to light only after three ...
...A vaccine which could protect children from mening...in Perth. Until now immunization against the disea...om the Vaccine Trials Group at the Telethon Instit...cess Margaret Hospital for Children, hope that th...
...Medicins Sans Frontiers(MSF), on Monday called for...s which are likely to be effective against extreme...highly prevalent, especially in sub Saharan Africa...t Borders(DWB) has urged that the regulatory bodie...
...Long trusted Turmeric the must have spice in every...h western scientists raving about its potential us...erative disorders thus vindicating the claims of s...of Ayurveda. According to a recent study conducte...
Other Medicine News:Health News:Faster Approval Procedures Urged For New TB Drugs 2(Date:1/7/2009)...-- ImQuest Life Sciences announced today the succe... and Drug Administration to initiate human clinica...tor IQP-0410. ImQuest anticipates initiating their...-0410 is a novel small molecule inhibitor of HIV w...nscriptase inhibitor (NNRTI). The compound possess...
(Date:1/6/2009)...s from prior U.S., U.K. and China Trials , , SA...nc. (VTI), a development stage company targeting l...as begun for a randomized, controlled, multi-cente...acorporeal Liver Assist Device (ELAD) as a treatme...er three protocols. The study is open for enrollme...
(Date:1/6/2009)...SNewswire/ -- Sequella, Inc., a clinical-stage bio...emic potential, announced today that SQ109, its le...s (TB), was the first drug approved for evaluation...ynport Vaccine Company LLC and Quintiles Transnati...ute of Allergy and Infectious Diseases (NIAID), Na...
(Date:1/5/2009)...lene Pharmaceuticals announced today that it has i...protein kinase inhibitor, CX-4945, in patients wit...ultiple myeloma. The primary endpoints of the oral..., tolerance and PK properties of CX-4945 and to se...addition, multiple mechanism-related pharmacodynam...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients 5035 1National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients 5035 2National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients 5035 3Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 1Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 2Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 3Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 4Rutgers research partner Stemcyte Inc expands to New Jersey 18164 1Rutgers research partner Stemcyte Inc expands to New Jersey 18164 2Go Speed Racer 21 Revving up the worlds fastest nanomotors 18161 1...CHKT, VANCOUVER, April 02, 2007 /PRNewswire-FirstC...) , a biotechnology company,developing chemokine-b...nd vascular diseases, today announced that the,Uni...stract,"Inhibition of primary growth and distant ...l of breast cancer" authored by Eugene H.,Huang, B...
...April 1, 2007--Researchers report that a,variation...ncer,risk and that this common variation may be re...cases in white men in the United States.,The resea...al,Cancer Institute (NCI), part of the National In...er Genetic Markers of Susceptibility,(CGEMS) initi...
Other Medicine Technology:M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 2M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 3M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 4Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 2Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 3Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 4... Rheumatoid Factor IgM enzyme linked immunosorbent...(RF IgM). Enzyme-linked immunosorbent assay method...M Rheumatoid Factor in human serum. The results of...gnosis of Rheumatoid Arthritis when supported by o...
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)
...r is a high precision optical system for corneal t...terior eye segment, based on a Revolving Dual Chan...GALILEI combines the advantages of two technologie...re data, while Scheimpflug imaging is optimal for ...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w
Medicine Products: